CYTOSTATIC ANTICANCER DRUG DEVELOPMENT - PRECLINICAL STUDIES AND EARLY CLINICAL-TRIALS (FRANKFURT MAIN, NOVEMBER 1989)

被引：0

作者：

BERDEL, WE ^{[1
]}

FIEBIG, HH ^{[1
]}

机构：

[1] UNIV FREIBURG,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,W-7800 FREIBURG,GERMANY

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 1990年 / 116卷 / 02期

关键词：

D O I：

10.1007/BF01612682

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：224 / 227

页数：4

共 50 条

[21] ROLE OF CLINICAL DRUG TRIAL METHODOLOGY WITH RESPECT TO STUDIES OF NEW DRUGS - CLINICAL-TRIALS OF TIMOLOL
KUPFER, C
SURVEY OF OPHTHALMOLOGY, 1979, 23 (06) : 399 - 401
[22] SEROQUEL - A PUTATIVE ATYPICAL ANTIPSYCHOTIC DRUG WITH SEROTONIN-RECEPTOR AND DOPAMINE-RECEPTOR ANTAGONIST PROPERTIES - PRECLINICAL AND EARLY CLINICAL-TRIALS IN SCHIZOPHRENIA
不详
JOURNAL OF CLINICAL PSYCHIATRY, 1995, 56 (09) : 438 - 445
[23] Can preclinical drug development help to predict adverse events in clinical trials?
Chi, Lap Hing
Burrows, Allan D.
Anderson, Robin L.
DRUG DISCOVERY TODAY, 2022, 27 (01) : 257 - 268
[24] The Role of Clinical Trials in Preclinical Alzheimer's Disease Drug Development Programs
Cummings, Jeffrey
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2020, 7 (04): : 288 - 290
[25] The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs
Jeffrey Cummings
The Journal of Prevention of Alzheimer's Disease, 2020, 7 : 288 - 290
[26] SOME FDA PERSPECTIVES ON DATA MONITORING IN CLINICAL-TRIALS IN DRUG DEVELOPMENT - CLOSING REMARKS
BROWN, BW
POCOCK, S
STATISTICS IN MEDICINE, 1993, 12 (5-6) : 615 - 616
[27] Cases studies of application of model-informed drug development in early phase clinical trials
ZHAO Wei
中国药理学与毒理学杂志, 2023, 37(S1) (S1) : 39 - 40
[28] BRITISH-BIOTECHNOLOGY-PLC GETS GO-AHEAD TO RECOMMENCE CLINICAL-TRIALS OF ANTICANCER DRUG BATIMASTAT
CLINE, H
BIOTECHNOLOGY LAW REPORT, 1995, 14 (04): : 597 - 598
[29] On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development
Lowe, P. J.
Hijazi, Y.
Luttringer, O.
Yin, H.
Sarangapani, R.
Howard, D.
XENOBIOTICA, 2007, 37 (10-11) : 1331 - 1354
[30] Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review
Theresa Pecho
Markus Zeitlinger
Clinical Pharmacokinetics, 2024, 63 : 13 - 26

← 1 2 3 4 5 →